Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 9/20 | 0.70 |
| ▸ | NPC1 | O15118 | 8/20 | 0.70 |
| ▸ | MAPT | P10636 | 5/20 | 0.70 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.70 |
| ▸ | ATM | Q13315 | 1/20 | 0.70 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.70 |
| ▸ | MMP2 | P08253 | 4/20 | 0.67 |
| ▸ | MMP9 | P14780 | 4/20 | 0.67 |
| ▸ | MMP8 | P22894 | 4/20 | 0.67 |
| ▸ | MMP13 | P45452 | 4/20 | 0.67 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7908000 | 0.88 | RAB9A (0.84) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL3202508 | 0.87 | RAB9A (0.70) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL16894054 | 0.86 | RAB9A (0.69) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL5716705 | 0.86 | RAB9A (0.56) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL5716710 | 0.86 | RAB9A (0.56) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL2245219 | 0.85 | MMP2 (0.85) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL6170277 | 0.84 | MEN1 (0.60) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL4510136 | 0.84 | RAB9A (0.65) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL4146732 | 0.83 | RAB9A (0.76) | RAB9ANPC1MAPTMCL1ATM | |
| SCHEMBL16894051 | 0.83 | RAB9A (0.76) | RAB9ANPC1MAPTMCL1ATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230233531-A1 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | UNIVERSITY OF HOUSTON SYSTEM | 2023-07-27 | — | — | US | disclosed |
| US-20230233531-A1 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | UNIVERSITY OF HOUSTON SYSTEM | 2023-07-27 | — | — | US | disclosed |
| US-7262318-B2 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER, INC. (US) | 2007-08-28 | — | — | US | disclosed |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PFIZER INC | 2006-11-16 | — | — | US | disclosed |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PFIZER INC | 2005-10-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230233531-A1 | USE OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS FOR TREATMENT OF INFLAMMATION | PTGES, PTGES2, PTGES3 | RAB9A 4016/4885NPC1 1269/4885MAPT 810/4885 |
| US-20050228015-A1 | Substituted heteroaryl- and phenylsulfamoyl compounds | PPARA, PPARG, PPARD | RAB9A 2271/4885NPC1 59/4885MAPT 1786/4885 |
| US-20060258723-A1 | Substituted Heteroaryl- and Phenylsulfamoyl Compounds | PPARG, PPARA, PPARD | RAB9A 2063/4885NPC1 74/4885MAPT 1984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.